<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04066998</url>
  </required_header>
  <id_info>
    <org_study_id>P/2019/424</org_study_id>
    <nct_id>NCT04066998</nct_id>
  </id_info>
  <brief_title>Cytokine Profile of Conjunctivitis, Performed Through Tears Analysis Among Patients Treated With Dupilumab</brief_title>
  <acronym>CYCLADDE</acronym>
  <official_title>Cytokine Profile of Conjunctivitis, Performed Through Tears Analysis Among Patients Treated With Dupilumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to assess the cytokine profile of tears in patients suffering from
      conjunctivitis versus patients without ocular involvement, when treated with Dupilumab
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2019</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increase of lacrimal inflammatory cytokines</measure>
    <time_frame>Month 8</time_frame>
    <description>Change in inflammatory cytokines in tears collected by capillary before and after treatment with Dupilumab. Analysis will be performed by flow cytometry. Concentrations of the following cytokines wil be measured: interleukin-1 β, interleukin-3, interleukin-4, interleukin-5, interleukin-6, interleukin-8, interleukin-10, interleukin-13, interleukin-17, interferon α, Tumor Necrosis Factor α.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of the increase of lacrimal inflammatory cytokines between the 2 groups</measure>
    <time_frame>Month 8</time_frame>
    <description>Change in inflammatory cytokines in tears collected by capillary among conjunctivitis patients versus non conjunctivitis patients, when treated with Dupilumab. Analysis will be performed by flow cytometry. Concentrations of the following cytokines wil be measured: interleukin-1 β, interleukin-3, interleukin-4, interleukin-5, interleukin-6, interleukin-8, interleukin-10, interleukin-13, interleukin-17, interferon α, Tumor Necrosis Factor α.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence/Presence of demodex</measure>
    <time_frame>Day 0</time_frame>
    <description>Presence of demodex on lashes before treatment with Dupilumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase of lacrimal eosinophiles</measure>
    <time_frame>Month 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of quality of life</measure>
    <time_frame>Month 8</time_frame>
    <description>Improvement of quality of life for patients treated with Dupilumab, assessed with Ocular Surface Disease Index (OSDI) questionnaire, scored from 0 (normal/no ocular involvement) to 100 (severe ocular disease)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Conjunctival Diseases</condition>
  <condition>Atopic Dermatitis</condition>
  <condition>Side Effect</condition>
  <arm_group>
    <arm_group_label>Conjunctivitis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients treated with Dupilumab with conjunctivitis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No conjunctivitis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients treated with Dupilumab and showing no signs of ocular involvement</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Tears sampling</intervention_name>
    <description>Tears sampling</description>
    <arm_group_label>Conjunctivitis</arm_group_label>
    <arm_group_label>No conjunctivitis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Lashes sampling</intervention_name>
    <description>Lashes sampling</description>
    <arm_group_label>Conjunctivitis</arm_group_label>
    <arm_group_label>No conjunctivitis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with severe atopic dermatitis resistant to main immunosuppressive drugs

          -  treated with Dupilumab

          -  with or without conjunctivitis

          -  postmenopausal women (since minimum 24 months), surgically sterilized women or women
             on contraception

        Exclusion Criteria:

        - pregnant or breastfeeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Camille FEBVAY, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Besançon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Louise VUILLEMEY, Int</last_name>
    <phone>033381669454</phone>
    <email>louise.vuillemey@orange.fr</email>
  </overall_contact>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 21, 2019</study_first_submitted>
  <study_first_submitted_qc>August 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2019</study_first_posted>
  <last_update_submitted>November 15, 2019</last_update_submitted>
  <last_update_submitted_qc>November 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctival Diseases</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

